Scarica l'app Stockscreener
24.24
0.33%
-0.08
Dopo l'orario di chiusura:
24.55
0.31
+1.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Precedente Chiudi:
$24.32
Aprire:
$24
Volume 24 ore:
654.44K
Relative Volume:
0.54
Capitalizzazione di mercato:
$2.96B
Reddito:
$460.48M
Utile/perdita netta:
$142.80M
Rapporto P/E:
20.54
EPS:
1.18
Flusso di cassa netto:
$221.79M
1 W Prestazione:
+5.03%
1M Prestazione:
-0.82%
6M Prestazione:
+19.47%
1 anno Prestazione:
+11.86%
Intervallo 1D:
$23.63
$24.25
Intervallo di 1 settimana:
$22.27
$24.94
Portata 52W:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Nome
Catalyst Pharmaceuticals Inc
Settore
Industria
Telefono
(305) 529-2522
Indirizzo
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
24.24 | 2.97B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.69 | 117.06B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.86 | 80.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
717.80 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.66 | 42.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
301.12 | 32.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-03-14 | Iniziato | Citigroup | Buy |
| 2024-03-07 | Iniziato | BofA Securities | Buy |
| 2023-12-21 | Iniziato | Oppenheimer | Outperform |
| 2022-08-24 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Ripresa | Piper Jaffray | Overweight |
| 2016-10-05 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Reiterato | ROTH Capital | Buy |
| 2014-09-16 | Reiterato | ROTH Capital | Buy |
| 2014-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2013-10-21 | Reiterato | Aegis Capital | Buy |
| 2013-09-24 | Iniziato | Maxim Group | Buy |
| 2013-09-06 | Reiterato | Aegis Capital | Buy |
| 2013-04-18 | Iniziato | Aegis Capital | Buy |
| 2012-08-27 | Aggiornamento | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Aggiornamento | Merriman | Sell → Neutral |
| 2009-05-29 | Downgrade | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Iniziato | Merriman Curhan Ford | Buy |
| 2007-11-28 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Iniziato | Stifel Nicolaus | Buy |
| 2007-01-05 | Iniziato | First Albany | Buy |
Mostra tutto
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
American Century Companies Inc. Purchases 770,198 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Immunovant Stock Surges 17% in 3 Months: What's Driving It? - TradingView
Zacks Research Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to Strong-Buy - MarketBeat
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Fundamental and Technical Setup - ChartMill
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know - TradingView
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Rafferty Asset Management LLC - MarketBeat
TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study - Finviz
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - TradingView
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now? - Yahoo Finance
Best Value Stocks to Buy for March 4th - Yahoo Finance Singapore
Catalyst Pharmaceuticals (CPRX) Stock Analysis: Uncovering a 41% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
CPRX: Citigroup Raises Price Target to $35.00, Maintains Buy Rat - GuruFocus
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Vanguard Group Inc. - MarketBeat
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Royce & Associates LP - MarketBeat
Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results - Insider Monkey
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Its Strong DCF Upside After Recent Flat Returns - Yahoo Finance
Why Catalyst Pharmaceuticals (CPRX) Is Down 5.0% After Issuing 2026 Guidance And Buyback PlanAnd What's Next - Sahm
CPRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc (CPRX) Q4 2025 Earnings Call Highli - GuruFocus
Catalyst Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y - Finviz
Earnings call transcript: Catalyst Pharmaceuticals Q4 2025 earnings beat expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Catalyst Pharmaceuticals Q4 2025 earnings beat expectations - Investing.com India
Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Catalyst Pharma Q4 Net Income Slips; Announces FY26 Outlook - RTTNews
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Shows Technical Setup for Potential Breakout - ChartMill
Catalyst Pharmaceuticals (CPRX) Net Margin Strength Reinforces Bullish Earnings Narrative - Sahm
Decoding Catalyst Pharmaceuticals Inc (CPRX): A Strategic SWOT I - GuruFocus
Catalyst Pharmaceuticals (NASDAQ:CPRX) Releases Quarterly Earnings Results, Beats Expectations By $0.26 EPS - MarketBeat
Catalyst Pharmaceuticals Q4 Non-GAAP Earnings Fall, Revenue Rises - marketscreener.com
Catalyst Pharma Posts Record 2025 Results, Raises 2026 Outlook - TipRanks
Catalyst Pharmaceuticals (CPRX) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (CPRX) Catalyst Pharmaceuticals Posts Q4 Revenue $152.6M, vs. FactSet Est of $142.7M - marketscreener.com
Earnings Flash (CPRX) Catalyst Pharmaceuticals Posts Q4 Adjusted EPS $0.68, vs. FactSet Est of $0.59 - marketscreener.com
Record 2025 growth and 2026 outlook at Catalyst Pharmaceuticals (Nasdaq: CPRX) - Stock Titan
CPRX | Catalyst Pharmaceutical Inc. FinancialsIncome Statement - Quiver Quantitative
Catalyst Pharmaceuticals Reports Record $589 Million in 2025 Revenues, Projects Continued Growth for 2026 - Quiver Quantitative
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance - The Manila Times
Catalyst Pharmaceuticals Reports Record Fourth Quarter and - GlobeNewswire
Catalyst Pharmaceuticals earnings on deck amid growth questions - Investing.com Nigeria
Catalyst Pharmaceuticals earnings on deck amid growth questions By Investing.com - Investing.com Canada
Catalyst: Q4 Financial Results Overview - Bitget
Catalyst Pharmaceuticals, Inc. (CPRX): Strong Buy Ratings and 43% Potential Upside Propel Investor Interest - DirectorsTalk Interviews
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference - The Manila Times
Aug Volume: Is Catalyst Pharmaceuticals Inc a defensive stockAnalyst Upgrade & Verified Chart Pattern Signals - baoquankhu1.vn
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc Azioni (CPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
2.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):